Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials

NCT00230828 Phase 3 COMPLETED

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Details

Lead sponsor	Solvay Pharmaceuticals
Phase	Phase 3
Status	COMPLETED
Start date	2005-05

Conditions

• Schizophrenia

Interventions

• bifeprunox